| Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward? H Kobat, I Elkonaissi, E Foreman, M O’Brien, MT Dorak, ... Journal of Oncology Pharmacy Practice 29 (3), 646-662, 2023 | 4 | 2023 |
| Smoking, Diabetes Mellitus, and Previous Cardiovascular Disease as Predictors of Anticancer Treatment-Induced Cardiotoxicity in Non–Small-Cell Lung Cancer: A Real-World Study H Kobat, I Elkonaissi, E Foreman, M Davidson, P Idaikkadar, M O'Brien, ... Clinical Lung Cancer 25 (1), e35-e42, 2024 | 3 | 2024 |
| Multiple cardiotoxicities during osimertinib therapy H Kobat, M Davidson, I Elkonaissi, E Foreman, S Nabhani-Gebara Journal of Oncology Pharmacy Practice, 10781552231164301, 2023 | 2 | 2023 |
| Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncology H Kobat, I Elkonaissi, MT Dorak, S Nabhani-Gebara Oncology Reviews 15 (1), 2021 | 2 | 2021 |
| Understanding cardio-oncology and potential impacts on patients H Kobat, C Booth, S Nabhani-Gebara | | 2022 |
| 1248P Osimertinib and crizotinib cardiotoxicity: Are real-world studies the way forward? H Kobat, I Elkonaissi, E Foreman, M O'Brien, S Nabhani-Gebara Annals of Oncology 32, S982, 2021 | | 2021 |
| International investigation of cardio-oncology practice H Kobat | | 2021 |
